The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease.
Hermanowicz S, Hermanowicz N.
Expert Rev Neurother · journal article · DOI 10.1586/14737175.2016.1158102 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för pimavanserin tartrate. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
12 träffarPimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers.
Ancoli-Israel S, Vanover KE, Weiner DM, Davis RE, van Kammen DP.
Sleep Med · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1016/j.sleep.2010.10.004Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist.
Snigdha S, Horiguchi M, Huang M, Li Z, Shahid M, Neill JC, Meltzer HY.
J Pharmacol Exp Ther · journal article · DOI 10.1124/jpet.109.156349Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders.
Abbas A, Roth BL.
Expert Opin Pharmacother · review; journal article · DOI 10.1517/14656560802532707A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.
Vanover KE, Betz AJ, Weber SM, Bibbiani F, Kielaite A, Weiner DM, Davis RE, Chase TN, Salamone JD.
Pharmacol Biochem Behav · research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.pbb.2008.04.010PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain.
Nordstrom AL, Mansson M, Jovanovic H, Karlsson P, Halldin C, Farde L, Vanover KE, Hacksell U, Brann MR, Davis RE, Weiner DM.
Int J Neuropsychopharmacol · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1017/s1461145707007869ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
Gardell LR, Vanover KE, Pounds L, Johnson RW, Barido R, Anderson GT, Veinbergs I, Dyssegaard A, Brunmark P, Tabatabaei A, Davis RE, Brann MR, Hacksell U, Bonhaus DW.
J Pharmacol Exp Ther · research support, non-u.s. gov't; journal article · DOI 10.1124/jpet.107.121715The effects of food on the pharmacokinetics of a formulated ACP-103 tablet in healthy volunteers.
Vanover KE, Robbins-Weilert D, Wilbraham DG, Mant TG, van Kammen DP, Davis RE, Weiner DM.
J Clin Pharmacol · comparative study; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1177/0091270007299361Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers.
Vanover KE, Robbins-Weilert D, Wilbraham DG, Mant TG, van Kammen DP, Davis RE, Weiner DM.
J Clin Pharmacol · randomized controlled trial; journal article · DOI 10.1177/0091270007299431ACP-103, a 5-HT2A receptor inverse agonist.
Roberts C.
Curr Opin Investig Drugs · review; journal articlePharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.
Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR, Davis RE.
J Pharmacol Exp Ther · journal article · DOI 10.1124/jpet.105.097006ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.
Li Z, Ichikawa J, Huang M, Prus AJ, Dai J, Meltzer HY.
Psychopharmacology (Berl) · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1007/s00213-005-0170-9